Phase 2 study for people with Myeloma

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 13 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Registry number NCT06297226
Started 21 March 2024 Today 16 October 2026 Estimated completion 31 July 2026

Past estimated completion. The registry still lists this trial as open, and the date it gave for finishing has been and gone. Confirm with the official record before you act on it.

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Royal Prince Alfred Hospital Camperdown NSW Recruiting
Royal Brisbane and Women's Hospital Brisbane QLD Recruiting
The Alfred Hospital Melbourne VIC Recruiting
St Vincent's Hospital Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 13 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 230

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria

* Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.

* Received at least 4 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT).

* Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.

* Participants must have measurable disease during screening.

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria

* Active or history of central nervous system involvement with MM.

* Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded.

* Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.

* Other protocol-defined Inclusion/Exclusion criteria apply.

Dates on the record

Started 21 March 2024
Estimated completion 31 July 2026
Registry last updated 6 October 2026
Checked by Voxsanity 13 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 6 October 2026.
  • This page last checked by Voxsanity: 13 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.